Buccolam (oromucosal midazolam), value-added buccal midazolam indicated for emergency treatment of children and adolescents from 3 months to 18 years with epilepsy suffering from prolonged acute convulsive seizures.
Lead Product(s): Midazolam
Therapeutic Area: Neurology Product Name: Buccolam
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 12, 2021
The Permira funds will support the management’s vision of becoming the leading CNS-focused specialty pharmaceutical platform in Europe through driving the commercialization of Neuraxpharm’s attractive new product pipeline and support further its expansion internationally.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Undisclosed
Partner/Sponsor/Collaborator: Permira Funds
Deal Size: $1,880.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition September 22, 2020